New insights for development of a safe and protective RSV vaccine.
New insights for development of a safe and protective RSV vaccine.
复制标题
DOI：
10.4161/hv.6.6.11562
复制
发表时间：
2010-06
期刊：
影响因子：
--
通讯作者：
Vogel SN
中科院分区：
文献类型：
--
作者：
Blanco JC;Boukhvalova MS;Shirey KA;Prince GA;Vogel SN
呼吸道合胞病毒(RSV)是婴幼儿及1岁以下儿童肺炎和毛细支气管炎的主要病因，在世界范围内造成严重的发病率和死亡率。目前还没有RSV疫苗。在20世纪60年代的S，福尔马林灭活呼吸道合胞病毒(FI-RSV)疫苗试验导致接种者自然感染时病情加重，包括两人死亡。这些疫苗试验造成灾难性结果的原因尚不清楚，但它们仍然是寻找新途径的引擎，以开发能够对这种重要病原体提供长期保护的安全疫苗。本文回顾了RSV疫苗发展的一些早期历史，以及关于RSV与宿主先天免疫反应和获得性免疫反应相互作用的更新信息。一种安全有效的RSV疫苗将需要对宿主对RSV的免疫反应进行“再教育”，以防止疫苗强化或严重的RSV疾病。
Respiratory Syncytial Virus (RSV) is the leading cause of pneumonia and bronchiolitis in infants and children <1 year old, resulting in significant morbidity and mortality worldwide. There is currently no RSV vaccine. In the 1960’s, a formalin-inactivated RSV (FI-RSV) vaccine trial led to exacerbated disease upon natural infection of vaccinees, including two deaths. The causes involved in the disastrous results of these vaccine trials are still unclear but they remain the engine for searching new avenues to develop a safe vaccine that can provide long-term protection against this important pathogen. This article reviews some of the early history of RSV vaccine development, as well as more recent information on the interaction between RSV and the host innate and adaptive immune responses. A safe and efficacious vaccine for RSV will require “re-education” of the host immune response against RSV to prevent vaccine-enhanced or severe RSV disease.